Fourth-generation cephalosporins

Clinical Microbiology Newsletter

Volumn 19, Issue 17, 1997, Pages 129-136

  Fung Tomc, Joan C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000927567     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(97)82485-3     Document Type: Article

References (24)

1. Hancock, R.E.W. and F. Bellido. 1992. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J. Antimicrob. Chemother. 29 (Suppl. A): 1-6.
2. Duval, J., et al. 1993. In-vitro antibacterial activity of cefepime: A multicenter study. J. Antimicrob. Chemother. 32 (Suppl B):55-61.
3. Liu, P.Y.-F., et al. 1995. Comparison of susceptibility to extended-spectrum β-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Diagn. Microbiol. Infect. Dis. 22:285-291.
4. Fekete, T., et al. Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Am. J. Med. 100 (Suppl. 6A):20S-25S.
5. Alcaide, F., et al. 1995. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob. Agents Chemother. 39:2243-2247.
6. Thomsberry, C., et al. 1993. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J. Antimicrob. Chemother. 32 (Suppl B):31-33.
7. Chong, Y., K. Lee., and O.H. Kwon. 1993. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic Gram-negative bacilli. J. Antimicrob. Chemother. 32 (Suppl. b):21-29.
8. Liu, Y.-C., W.-K. Huang, and D.-L. Cheng. 1994. Antibacterial activity of cefepime. Chemotherapy 40:384-390.
9. Ishida, Y., et al. 1995. In vitro and in vivo activity of DQ-2556, a new cephalosporin. Chemotherapy 41:5-13.
10. Tanaka, M., M. Otsuki, and T. Nishino 1992. In vitro and in vivo activities of DQ-2556 and its mode of action. Antimicrob. Agents Chemother. 36:2595-2601.
11. Murphy, S.P., M.E. Erwin, and R.M. Jones. 1994. Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. Diagn. Microbial. Infect. Dis. 20:49-55.
12. Neu, H.C., N.-X. Chin, and H.-B. Huang. 1993. In vitro activity and β-lactamase stability of FK-037, a parenteral cephalosporin. Antimicrob. Agents Chemother. 37:566-573.
13. Washington, J.A., et al. 1993. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob. Agents Chemother. 37:1696-1700.
14. Sprangler, S.K., et al. 1994. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefo-taxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob. Agents Chemother 38:898-900.
15. Jones, R.N., M.S. Barrett, and M.E. Erwin. 1994. In-vitro activity of FK-037, a new patenteral cephalosporin. J. Antimicrob. Chemother. 33:137-144.
16. Martínez-Beltrán, J. et al. 1995. Multicenter comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin. Eur. J. Clin. Microbiol. Infect. Dis. 20:27-32.
17. Clarke, A.M., S.J.V. Zemcov, and M.M. Hubinette. 1994. Comparative in vitro activity of FK-037, a new cephalosporin antibiotic. Diagn. Microbiol. Infect Dis. 20:27-32.
18. Kessler, R.E., et al. 1985. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob. Agents Chemother. 27:207-216.
19. Thornsberry, C., and Y. Cheung. 1996. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J. Med. 100 (Suppl. 6A):26A-38S.
20. Yokota, T., K. Arai, and E. Suzuki. 1991. Cefpirome, its in vitro antibacterial activity, binding affinity to the site of action, PBPs, and synergy of bac-teridical effect with serum complement or mouse cultured macrophages. Chemotherapy 39 (Suppl. 1):11-20.
21. Bergeron, M.G., and M. Bernier. 1994. Bactericidal activity of cefpirome (HR 810) agains Gram-negative bacteria isolated form blood of septicemic patients. Infections 22:299-305.
22. Jones, R.N., et al. 1991. Antimicrobial activity of E-1040, a novel thidiazolyl cephalosporin compared with other parenteral cephems. Diagn. Microbiol. Infect. Dis. 14:301-309.
23. Watanabe, N.-A., R. Hiruma, and K. Katsu. 1992. In vitro evaluation of E1077, a new cephalosporin with a broad antibacterial spectrum. Antimi-crob. Agents Chemother. 36:589-597.
24. Fujimoto, T. et al. 1990. In-vitro antibacterial activity of DQ-2556 and its stability to various β-lactamases. J. Antimicrob. Chemother. 26:329-341.